Emerging Role of Immunotherapy for Childhood Cancers Emerging Role of Immunotherapy for Childhood Cancers

Immunotherapeutic strategies are showing promise for pediatric cancers such as leukemia and neuroblastoma. What is the latest research?Chinese Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Related Links:

Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion We observed increased risks of CNS tumors in offspring after parental employment in painting and printing industries. Children of fathers employed in painting and printing industries had a two-fold increase in AML. PMID: 30838423 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
Abstract We aimed to investigate the differences in cancer incidence between boys and girls. The incidence data for pediatric cancer were retrieved from the International Incidence of Childhood Cancer. Poisson regression was applied to detect the gender differences in cancer incidence at global and regional levels. Boys were more susceptible to childhood cancers than girls, with a global boy-to-girl incidence rate ratio (IRR) of 1.27 (95% confidence intervals [CI] 1.26-1.28) for leukaemia, 1.48 (95% CI 1.46-1.51) for lymphomas, 1.10 (95% CI 1.08-1.11) for central nervous system neoplasms, 1.11 (95% CI 1.08-1.13) f...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
CONCLUSION: Childhood cancer survivors are at an increased risk of hyperthyroidism, potentially resulting in non-endocrine morbidity. PMID: 30585514 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
The first two authors and last two authors contributed equally.Genome-wide association studies (GWAS) have identified risk loci for Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL) and Non-Hodgkin Lymphoma, however an Acute Myeloid Leukemia (AML) GWAS has not been published to date. We performed a GWAS to identify AML and Myelodysplastic Syndrome (MDS) risk loci using a nested case-control study design in the DISCOVeRY-BMT cohorts which includes almost 2000 AML and MDS patients as cases and 2813 unrelated donors as controls.Genotyping was performed using the Illumina Human OmniExpress BeadChip and i...
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Source Type: research
Precision medicine has significant potential to improve therapy options for patients who have exhausted treatment options for their relapsed or refractory cancers. Next-generation sequencing has enabled the detection of genetic abnormalities in individual tumours that bestow sensitivity to selective agents targeting these dysregulated cellular pathways. Several programs have recently launched that utilize sequencing technology to identify patient mutations and match the patients to clinical trials for agents that target the dysregulted pathway. The Pediatric MATCH trial initiated by the National Cancer Institute (NCI) and ...
Source: Blood - Category: Hematology Authors: Tags: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II Source Type: research
ConclusionsOur preliminary data demonstrate that NB patients at risk of developing secondary leukemia can be identified by molecular profiling of BM aspirates obtained during routine disease surveillance for NB. These findings present an opportunity for the development of early detection studies for patients with pediatric malignancies undergoing intensive therapy and importantly inform studies into mechanisms of leukemic transformation and specific gene-treatment effects.DisclosuresCheung: Ymabs: Patents &Royalties.
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis II Source Type: research
ConclusionsSES significantly mediates racial/ethnic childhood cancer survival disparities for several cancers. However, the proportion of the total race/ethnicity –survival association explained by SES varies between black‐white and Hispanic‐white comparisons for some cancers, and this suggests that mediation by other factors differs across groups.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Conditions:   Neuroblastoma;   Rhabdomyosarcoma;   Ewing Sarcoma Family of Tumors;   Osteosarcoma;   Leukemia;   Central Nervous System Tumor Intervention:   Other: Sampling on blood, bone marrow and cerebrospinal fluid Sponsor:   Institut Curie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: 25 February 2016 Source:The Lancet, Volume 387, Supplement 1 Author(s): Aysha Patel, Christine Thevanesan, John Anderson, Martin Pule, Karin Straathof Background High risk neuroblastoma poses a significant clinical problem in paediatric oncology and new treatment strategies are needed. Antibody therapy specific for neuroblastoma surface molecule GD2 has been shown to improve outcome. Here we develop a new generation antibody-based therapeutic agent named BiTE (Bi-specific T cell Engager) that combines antibody specificity with potent T cell functions. Methods To identify the BiTE format with maxim...
Source: The Lancet - Category: Journals (General) Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Childhood Cancer | China Health | Health | Hematology | Immunotherapy | Leukemia | Neuroblastoma | Neurology | Pediatrics